Exact Sciences Hikes Its Full-Year Outlook. But There's One First-Quarter Drawback.Investors Business Daily • 05/01/25
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025Business Wire • 04/29/25
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/24/25
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.Investors Business Daily • 04/17/25
Tap Into the Silver Economy Boom With These Aging Demographics StocksZacks Investment Research • 04/14/25
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic GroupsBusiness Wire • 04/14/25
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer ScreeningBusiness Wire • 03/31/25
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply ChainInvestors Business Daily • 03/27/25
New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare EfficiencyBusiness Wire • 03/12/25
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/YZacks Investment Research • 02/20/25
U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of a Second Patent Asserted by Exact SciencesBusiness Wire • 02/18/25
Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease TestingBusiness Wire • 02/05/25
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI SymposiumBusiness Wire • 01/21/25